Protalix BioTherapeutics (PLX) EBIT (QoQ) (2010 - 2026)
Powered by 
Analysis
Protalix BioTherapeutics (PLX) EBIT (QoQ) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.74 Bn | 192.75 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.96 Bn | 176.78 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.20 Bn | 123.35 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.05 Bn | 74.05 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.28 Bn | 55.10 Bn | 1.37 Bn |
| 6 | Moderna | 53.67 Bn | 48.54 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.08 Bn | 29.78 Bn | 992.69 Mn |
| 8 | Biogen | 31.91 Bn | 30.62 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.22 Bn | 29.22 Bn | 1.16 Mn |
| 10 | Protalix BioTherapeutics | 217.96 Mn | 177.31 Mn | 12.13 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -77.91% |
| Mar 31, 2026 | 553.97% |
| Dec 31, 2025 | -318.58% |
| Sep 30, 2025 | 81.83% |
| Jun 30, 2025 | 128.28% |
| Mar 31, 2025 | -157.50% |
| Dec 31, 2024 | 80.63% |
| Sep 30, 2024 | 264.44% |
| Jun 30, 2024 | 50.02% |
| Mar 31, 2024 | 13.52% |
| Dec 31, 2023 | -197.56% |
| Sep 30, 2023 | -109.24% |
| Jun 30, 2023 | 930.46% |
| Mar 31, 2023 | 1.44% |
| Dec 31, 2022 | 20.16% |
| Sep 30, 2022 | 43.43% |
| Jun 30, 2022 | -195.40% |
| Mar 31, 2022 | 67.23% |
| Dec 31, 2021 | -202.71% |
| Sep 30, 2021 | 79.43% |